iLIVER最新文献

{"title":"Optimizing postoperative chemotherapy for ampullary cancer: A risk-driven approach to precision care","authors":"Di Zhang ,&nbsp;Yuan Zheng ,&nbsp;Mingru Liu ,&nbsp;Jiaoyang Lu","doi":"10.1016/j.iliver.2025.100166","DOIUrl":"10.1016/j.iliver.2025.100166","url":null,"abstract":"<div><h3>Background and aims</h3><div>This research aimed to develop an innovative predictive model for estimating overall survival (OS) in patients with ampullary carcinoma and to evaluate the clinical benefits of postoperative chemotherapy (POCT) tailored to individual risk profiles.</div></div><div><h3>Methods</h3><div>Data from patients with ampullary carcinoma were retrospectively analyzed. Multivariable analysis identified key prognostic factors, which were incorporated into a predictive nomogram. The impact of POCT on OS was assessed within risk groups stratified by the nomogram.</div></div><div><h3>Results</h3><div>Data for 3921 patients were included, with 2744 in the training cohort and 1177 in the validation cohort. A nomogram incorporating age, sex, tumor grade, T stage, N stage, and tumor size outperformed the TNM staging system, with areas under the curve for 3-year, 5-year, and 8-year OS of 0.755 vs 0.687, 0.752 vs 0.694, and 0.750 vs 0.694, respectively, in the training cohort and 0.705 vs 0.664, 0.717 vs 0.679, and 0.734 vs 0.703 in the validation cohort. Calibration plots showed excellent agreement between predicted and observed survival outcomes. Decision curve analysis indicated a net benefit across threshold probabilities above that of TNM staging. Risk stratification based on the model indicated that high-risk patients had a significantly increased mortality risk (<em>p</em> &lt; 0.001). Notably, POCT significantly improved OS in high-risk patients (<em>p</em> &lt; 0.001) but not in low-risk patients.</div></div><div><h3>Conclusion</h3><div>Not all patients benefit from POCT. The proposed nomogram predicts survival effectively and can guide treatment decisions, optimizing outcomes by providing additional chemotherapy for high-risk patients while sparing low-risk patients from unnecessary treatment.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 2","pages":"Article 100166"},"PeriodicalIF":0.0,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice revolution in local interventional therapy for liver metastases","authors":"Hongjun Yuan ,&nbsp;Hongli Yu ,&nbsp;Ying Guan ,&nbsp;Wenjing Wang ,&nbsp;Qiang Yu ,&nbsp;Yinying Lu ,&nbsp;Fengyong Liu","doi":"10.1016/j.iliver.2025.100164","DOIUrl":"10.1016/j.iliver.2025.100164","url":null,"abstract":"<div><div>The treatment of liver metastases is undergoing a transformation from single-modality therapy to multimodal combination therapy, with local interventional treatments playing an increasingly important role. This review explores the synergistic effects between local interventional therapy and systemic treatment, the reconstruction of interventional therapy indications driven by advances in systemic treatment, and the impact of local interventional therapy on systemic treatment “switching” strategies. Through multidisciplinary collaboration and innovative interventional materials and techniques, local interventional therapy has evolved from a traditional palliative approach to become an essential component in the comprehensive treatment system for liver metastases.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 2","pages":"Article 100164"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy analysis of hepatic arterial infusion chemotherapy combined with sintilimab and bevacizumab for initially unresectable hepatocellular carcinoma","authors":"Zhu Chen,&nbsp;Xingyu Chen,&nbsp;Haiyang Hu,&nbsp;Kai Chen,&nbsp;Chengyou Du,&nbsp;Heng Xiao,&nbsp;Xiang Lan","doi":"10.1016/j.iliver.2025.100163","DOIUrl":"10.1016/j.iliver.2025.100163","url":null,"abstract":"<div><h3>Background and aims</h3><div>Hepatocellular carcinoma (HCC) presents a significant challenge in tumor management because of its low resection rates. Conversion therapy aims to transform unresectable tumors into resectable ones through local treatments, thereby providing surgical options for some patients with HCC. However, the overall strategies and efficacy of conversion therapy for HCC remain inadequately defined. This study was performed to evaluate the efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab in patients with unresectable liver cancer.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of patients with initially unresectable HCC who received HAIC in conjunction with sintilimab and bevacizumab. Preoperative demographic data, tumor markers, tumor size, tumor count, conversion outcomes, and surgery-related clinical data were collected and analyzed before and after treatment.</div></div><div><h3>Results</h3><div>Twelve patients were included in this study. All patients exhibited satisfactory antitumor effects. Ten patients underwent one or two treatment cycles, while two completed four cycles. The mean alpha-fetoprotein level decreased from 73,471 ± 138,239 to 2374 ± 6325 ng/mL, and the mean tumor size decreased from 11.4 ± 2.2 to 7.6 ± 1.0 cm. Following evaluation, 10 patients were successfully converted, with 6 ultimately undergoing curative liver cancer resection; of these 6 patients, 4 achieved a pathological complete response.</div></div><div><h3>Conclusion</h3><div>The combination of HAIC with sintilimab and bevacizumab represents a safe and effective strategy for tumor conversion. This approach can achieve significant tumor reduction and favorable effects on portal vein tumor thrombus within a short timeframe, facilitating curative resection of liver cancer.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 2","pages":"Article 100163"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and progress in techniques of precision liver surgery","authors":"Si-Yuan Wang,&nbsp;Tao Zhang,&nbsp;Tian Yang,&nbsp;Jia-Hong Dong","doi":"10.1016/j.iliver.2025.100158","DOIUrl":"10.1016/j.iliver.2025.100158","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 2","pages":"Article 100158"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated intrahepatic bile duct injury secondary to blunt abdominal trauma: A case report and literature review","authors":"Shengming Zhang ,&nbsp;Yifeng He ,&nbsp;Daiwei Zhou ,&nbsp;Jianhong Jiang,&nbsp;Jianfan Wen,&nbsp;Deqin Zeng","doi":"10.1016/j.iliver.2025.100156","DOIUrl":"10.1016/j.iliver.2025.100156","url":null,"abstract":"<div><div>Closed trauma-induced extrahepatic bile duct injuries have been occasionally reported. However, isolated intrahepatic bile duct injuries are extremely rare due to the deep location of the intrahepatic bile ducts and the protection provided by surrounding vital blood vessels and organs.</div><div>We report a case of a 50-year-old female who sustained an incomplete rupture of the left hepatic bile duct following a car accident. The patient was urgently transferred to a nearby hospital for treatment after the incident. On the 15th day of hospitalization, she developed abdominal distension, nausea, indigestion, and white stool. Large volumes of dark green ascitic fluid were drained via ultrasound-guided abdominal paracentesis. The patient requested further specialized diagnosis and treatment and was subsequently transferred to our hospital. Ultimately, percutaneous transhepatic cholangiography (PTC) revealed contrast agent extravasation from the left intrahepatic bile duct, confirming a traumatic bile duct injury. The patient underwent left hemihepatectomy on the 30th day post-injury and was discharged on the 12th postoperative day following a successful recovery.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 2","pages":"Article 100156"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring emerging frontiers in hepatology: iLIVER's continuing journey","authors":"Ming-Da Wang ,&nbsp;Xin-Fei Xu ,&nbsp;Lei Cai,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2025.100148","DOIUrl":"10.1016/j.iliver.2025.100148","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100148"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143591611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contrast-enhanced US and contrast-enhanced CT for diagnosis of focal liver lesions in liver transplant recipients: A comparative study","authors":"Nong Gao ,&nbsp;Dongli Wang ,&nbsp;Xiuzhu Ma ,&nbsp;Faqin Lv ,&nbsp;Xiuyun Ren","doi":"10.1016/j.iliver.2025.100147","DOIUrl":"10.1016/j.iliver.2025.100147","url":null,"abstract":"<div><h3>Background and aims</h3><div>Contrast-enhanced ultrasound (CEUS) is widely used in the diagnosis of complications after liver transplantation. This study compared the diagnostic efficacy of CEUS with that of contrast-enhanced computed tomography (CECT) for focal liver lesions in liver transplant recipients.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed 115 liver transplant recipients who were diagnosed to have focal liver lesions at our hospital between June 2015 and June 2023. All patients were examined by CEUS and CECT and had a definitive pathological diagnosis. Based on the diagnostic outcomes, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of these imaging modalities in differentiating between benign and malignant lesions were calculated using a four-table method. Differences in diagnostic efficacy between CEUS and CECT with respect to pathological findings were compared using the chi-squared test and Fisher's exact test. The consistency of diagnosis between these modalities was assessed using the linear weighted kappa test.</div></div><div><h3>Results</h3><div>CEUS identified 79 malignant and 36 benign lesions, while CECT detected 81 malignant and 34 benign lesions. The sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of CEUS and CECT in diagnosis of focal lesions in transplanted livers were 95.7% vs 97.2%, 97.2% vs 96.1%, 97.9% vs 97.5%, 97.2% vs 98.6%, and 96.4% vs 97.1%, respectively. Both CEUS and CECT demonstrated comparable diagnostic efficacy (κ = 0.899). CEUS showed strong diagnostic consistency with pathological results (κ = 0.912) and was more effective than CECT in diagnosing focal normal liver tissue and fat infiltration (<em>p</em> &lt; 0.05). Both methods were equally effective for diagnosis of focal inflammatory lesions, infarction, and hemangioma.</div></div><div><h3>Conclusion</h3><div>CEUS is as effective as CECT for diagnosis of benign and malignant lesions in transplanted livers but surpasses CECT in differentiating benign lesions, particularly focal normal liver tissue and fat infiltration.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100147"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment for unresectable hepatocellular carcinoma patients: Options and management after complete response","authors":"Jin-Ming Wang ,&nbsp;Guo-Gao Qiu ,&nbsp;Zhi-Dong Liu ,&nbsp;Jia-Yong Su ,&nbsp;Da-Long Yang ,&nbsp;Zhu-Jian Deng ,&nbsp;Zhi-Cheng Li ,&nbsp;Jian-Hong Zhong","doi":"10.1016/j.iliver.2025.100145","DOIUrl":"10.1016/j.iliver.2025.100145","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100145"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143480325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itaconate facilitates methane-induced Nrf2 pathway activation for mitigating liver ischemia and reperfusion injury","authors":"Tianyi Zhang ,&nbsp;Danfeng Fan ,&nbsp;Kewei Qin ,&nbsp;Hongtao Lu ,&nbsp;Linwei Zhao ,&nbsp;Kexin Liu ,&nbsp;Pei Zhang ,&nbsp;Qiang Sun ,&nbsp;Zhouheng Ye","doi":"10.1016/j.iliver.2025.100144","DOIUrl":"10.1016/j.iliver.2025.100144","url":null,"abstract":"<div><h3><em>Background and aims</em></h3><div>Methane has shown protective effects against ischemia and reperfusion injury (IRI) in the liver, but the mechanism underlying these beneficial effects is unclear. To investigate the hypothesis that itaconate facilitates in methane-induced Nrf2 pathway activation to mitigate liver IRI.</div></div><div><h3><em>Methods</em></h3><div>An oxygen and glucose derivation (OGD) model using RAW 264.7 cells and a liver IRI model in mice were established. Methane's beneficial effects were assessed through hematoxylin and eosin (HE) staining, Suzuki's score, serum alanine transferase level, superoxide dismutase (SOD) level, malondialdehyde (MDA) level, and cell viability. The relative expression levels of Nrf2, its downstream molecules and some inflammatory factors were detected via western blotting. Itaconate levels were analyzed using liquid chromatography. RAW 264.7 cells were transfected with short hairpin RNA targeting mouse aconitate decarboxylase 1 (Acod1) mRNA for itaconate downregulation.</div></div><div><h3><em>Results</em></h3><div>Methane significantly alleviated liver IRI, as shown by the significant reduction in Suzuki's scores and alanine transferase (ALT) levels in vivo. Methane treatment significantly increased MTT and SOD levels and decreased MDA levels in the OGD injury model in vitro. Methane also increased the total and nuclear Nrf2 expression levels, activated downstream molecules including heme oxygenase-1 (HO-1), NQO1 and affected the production of inflammatory cytokines such as IL-10, IL-1β, and IL-12. Itaconate levels were significantly elevated after methane treatment compared with the OGD injury group. The protective effects of methane were abolished after itaconate downregulation through <em>Acod1</em> knockdown.</div></div><div><h3><em>Conclusions</em></h3><div>Methane alleviates liver IRI through itaconate/Nrf2 pathway activation, with itaconate being critical for methane's beneficial effects.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100144"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAGI2-AS3/miR-450b-5p/COLEC10 interaction network: A potential therapeutic and prognostic marker in hepatocellular carcinoma","authors":"Lan-Qing Yao ,&nbsp;Yong-Kang Diao ,&nbsp;Jin-Bo Gong ,&nbsp;Li-Hui Gu ,&nbsp;Jia-Hao Xu ,&nbsp;Ming-Da Wang ,&nbsp;Chao Li","doi":"10.1016/j.iliver.2025.100146","DOIUrl":"10.1016/j.iliver.2025.100146","url":null,"abstract":"<div><h3><em>Background and aims</em></h3><div>Hepatocellular carcinoma (HCC) is a prevalent malignancy with poor prognosis. This study uses integrated bioinformatic analyses to explore potential competing endogenous RNA (ceRNA) network chains in HCC.</div></div><div><h3><em>Methods</em></h3><div>HCC expression profile data were obtained from the Gene Expression Omnibus dataset, and differential expression analysis was conducted to identify differentially expressed mRNAs (DEmRNAs), microRNAs (DEmiRNAs), and long non-coding RNAs (DElncRNAs) between HCC and normal liver tissue samples. Univariate Cox regression analysis was performed to identify mRNAs associated with the prognosis of HCC patients. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were used to classify the identified genes functionally. Cytoscape software was used to construct a protein–protein interaction network. Using the intersection method, a ceRNA network was established to align data from two databases (miRTarBase and miRcode). Pearson correlation analysis was conducted to evaluate the relationships between lncRNAs and mRNAs.</div></div><div><h3><em>Results</em></h3><div>A total of 106 prognosis-related DEmRNAs were identified between HCC and normal samples. A total of 132 DEmiRNAs and 42 DElncRNAs were dysregulated in HCC. A ceRNA network of three lncRNAs, six miRNAs, and eight mRNAs was constructed. High expression of MCM10, CDKN3, RRM2, KIF3A, and ALYREF correlated with a poor prognosis, while high expression of CPEB2, COLEC10, and PBLD was associated with a better prognosis for HCC patients. Expression analysis confirmed the differential expression of these genes in HCC samples. Correlation analysis revealed that a MAGI2-AS3/hsa-miR-450b-5p/COLEC10 axis might play a crucial role in the progression of HCC.</div></div><div><h3><em>Conclusion</em></h3><div>The ceRNA network constructed could provide insight into HCC tumorigenesis and might lead to new molecular biomarkers for diagnosing and treating HCC.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 1","pages":"Article 100146"},"PeriodicalIF":0.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}